Probiotics in the management of inflammatory bowel diseases?

American Journal of Gastroenterology

Volumn 102, Issue SUPPL. 1, 2007, Pages s22-s28

  Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CULTURAO; GENTAMICIN; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOMODULATING AGENT; MESALAZINE; NISSLE 1917; PLACEBO; PREBIOTIC AGENT; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR; UCC 118; UNCLASSIFIED DRUG; VSL3;

BACTEREMIA; BACTERIUM; BIFIDOBACTERIACEAE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DENDRITIC CELL; ENTERITIS; ENTEROBACTERIACEAE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; ILEITIS; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; INTESTINE; INTESTINE MUCOSA; LACTOBACILLUS; PRIORITY JOURNAL; PROCTITIS; REMISSION; ULCERATIVE COLITIS;

EID: 34249790126     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01295.x     Document Type: Conference Paper

References (39)

1. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002 122 : 44 54.
2. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995 102 : 448 55.
3. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996 38 : 365 75.
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 6.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
6. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003 124 : 993 1000.
7. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53 : 1658 64.
8. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 307 : 731 4.
9. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004 10 : 286 99.
10. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 2004 126 : 1620 33.
11. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999 354 : 635 9.
12. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004 20 : 1133 41.
13. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005 54 : 242 9.
14. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005 100 : 1539 46.
15. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003 15 : 697 8.
16. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003 37 : 42 7.
17. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997 11 : 853 8.
18. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 53 : 1617 23.
19. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999 13 : 1103 8.
20. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003 22 : 56 63.
21. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 1567 74.
22. Shanahan F, Guraner F, von Wright A, et al. A one year, randomised, double-blind, placebo controlled trial of a lactobacillus or a bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006 130 (Suppl 2 A44.
23. Gionchetti P, Amadini C, Rizzello F, et al. Probiotics-role in inflammatory bowel disease. Dig Liver Dis 2002 34 (Suppl 2 S58 62.
24. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004 53 : 108 14.
25. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003 124 : 1202 9.
26. Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactovacillus rhammnosus GG. Dis Colon Rectum 2004 47 : 846 84
27. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003 17 : 509 15.
28. Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005 40 : 43 51.
29. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000 31 : 453 7.
30. McCarthy J, O'Mahony L, Dunne C. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease. Gut 2001 49 (Suppl III A2447.
31. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004 4 : 5.
32. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997 25 : 653 8.
33. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000 45 : 1462 4.
34. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005 11 : 833 9.
35. Campieri M, Rizzello F, Venturi A. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gastroenterology 2000 118 : A781.
36. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002 51 : 405 9.
37. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006 55 : 842 7.
38. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003 36 : 775 80.
39. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 2002 50 (Suppl 3 III54 9.